Updates are available Correction dated 2025-03-21
Click to view Correction: https://doi.org/10.1038/s41467-025-57678-w
-
Authors
Reszetnik, Grace
Hammond, Keely
Mahshid, Sara https://orcid.org/0000-0003-4203-819X
AbdElFatah, Tamer https://orcid.org/0000-0003-4141-2442
Nguyen, Dao https://orcid.org/0000-0003-4012-5441
Corsini, Rachel
Caya, Chelsea
Papenburg, Jesse
Cheng, Matthew P. https://orcid.org/0000-0002-4867-2063
Yansouni, Cedric P. https://orcid.org/0000-0002-4765-3469
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 28 October 2024
First Online: 9 November 2024
Change Date: 21 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-57678-w
Competing interests
: The authors declare the following competing interests. S.M., D.N., and C.P.Y. co-supervised the work in the publication describing the PhenEXA system. C.P.Y. reports being on an Independent Data Monitoring Committees (IDMC) for Medicago Inc. and InventVacc Biologicals Inc., unrelated to the submitted work. M.P.C. reports personal fees from GEn1E Lifesciences (as a member of the scientific advisory board), personal fees from nplex biosciences (as a member of the scientific advisory board), outside the submitted work. He is the co-founder of Kanvas Biosciences and owns equity in the company. In addition, M.P.C. has a patent Methods for detecting tissue damage, graft versus host disease, and infections using cell-free DNA profiling pending, and a patent Methods for assessing the severity and progression of SARS-CoV-2 infections using cell-free DNA pending. J.P. reports grants from MedImmune, Merck; personal fees from Astra-Zeneca and Merck, all outside the submitted work. All other Authors declare no competing interests.
